Research-Grade Peptides | 99%+ Purity Verified | US Delivery 2–5 Days
Save 5% with Crypto
SaiyanMed

Your Cart

No products in the cart.

What Is MOTS-c | Mitochondrial-Derived Peptide for Cellular Metabolism Research

Research Use Only Notice: This article discusses MOTS-c only as a laboratory research reagent. It covers published cell studies, laboratory animal-model research, analytical testing, and routine laboratory handling.MOTS-c must not be consumed, administered to humans, used in veterinary practice, or used for diagnosis, treatment, cosmetic purposes, body-weight control, or performance enhancement.

Any concentration mentioned below refers only to the cited laboratory experiment and is not a human or veterinary dose.

What Is MOTS-c

MOTS-c is a 16-amino-acid peptide first reported in 2015 by Lee and colleagues. Its sequence is MRWQEMGYIFYPRKLR, its molecular formula is C101H152N28O22S2, and its average molecular weight for the free peptide moiety is approximately 2,174.6 g/mol (monoisotopic exact mass, 2,174.11 Da; monoisotopic mass, 2,173.11 Da).

The CAS Registry Number, as listed in PubChem (CID 155885767), is 1627580-64-6.

Researchers identified its coding region within the mitochondrial 12S ribosomal RNA region and studied it as a possible signal between mitochondria and the rest of the cell.[1][2][3]

Most published findings come from cultured cells and laboratory mouse models. These studies link MOTS-c with changes in folate-related metabolism, purine synthesis, AMPK signalling, stress responses, and gene regulation.

They do not show that MOTS-c is safe or effective for human or veterinary use.

Basic Information

Item Information
Full name Mitochondrial open reading frame of the 12S rRNA type-c
Short name MOTS-c
Length 16 amino acids
Sequence MRWQEMGYIFYPRKLR[3]
Molecular formula C101H152N28O22S2[1]
Average molecular weight (free peptide) Approximately 2,174.6 g/mol, excluding counterions, water, salts, and residual solvents; monoisotopic exact mass 2,174.11 Da[1]
PubChem CID 155885767[1]
CAS Registry Number (as listed in PubChem) 1627580-64-6[1]
Mitochondrial region The short open reading frame was reported within the 12S rRNA region. MT-RNR1 is the mitochondrial gene for 12S rRNA, Gene ID 4549.[2][3]
Solubility No single solubility value should be assumed for every batch. Solubility can change with the counterion, purity, concentration, pH, salt level, and buffer. Test a small amount in the intended laboratory buffer before preparing the full stock.
Storage Follow the batch-specific label, COA, and stability information. Keep dry material tightly closed and protected from moisture and light. Do not assign a solution shelf life or freeze-thaw limit without supporting stability data.

Where MOTS-c Comes From

The human mitochondrial genome is usually described as carrying 13 conventional protein-coding genes, 22 tRNA genes, and two rRNA genes.

MOTS-c was reported from a much shorter open reading frame inside the mitochondrial 12S rRNA region, showing that small mitochondrial RNA regions may contain information for short peptides that were not included in the older gene annotation.[3]

The discovery paper reported that MOTS-c is translated in the cytoplasm rather than by the normal mitochondrial translation system. This conclusion was based in part on differences between the standard genetic code and the vertebrate mitochondrial genetic code.

The exact steps by which the RNA reaches the cytoplasm are still not fully known.[3]

What Laboratory Studies Have Found

In the original cell and mouse-model study, MOTS-c was linked with changes in the methionine-folate cycle and de novo purine synthesis.

The study also reported an increase in AICAR, followed by AMPK activation.[3] AICAR is a metabolite that can affect AMPK, a protein that helps cells respond to changes in energy supply.

This evidence supports a link between MOTS-c and these metabolic pathways, but it does not prove that MOTS-c directly binds to or directly blocks ATIC, MTHFD1, MTHFD2, or another single enzyme.

Direct binding would need separate tests such as purified-enzyme studies, binding assays, or structural analysis.

A later cell study found that metabolic stress caused MOTS-c to move into the nucleus in an AMPK-dependent way.

Chromatin and gene-expression analyses suggested that nuclear MOTS-c associates with DNA regions enriched in antioxidant response elements (AREs) and influences gene networks related to NRF2-mediated stress responses.

That study did not establish a direct physical interaction between MOTS-c and the NRF2 protein; it identified more direct associations with transcription factors such as ATF1, ATF7, and JUND.[4]

Another study used C2C12 mouse myoblasts under metabolic stress conditions (0.5 g/L glucose, 1% FBS for 48 hours).

  • In that model, 10 µM MOTS-c produced an approximately two-fold protective effect on cell survival under glucose-restricted and serum-deprived conditions (P = 2.57 × 10−25, n = 12).
  • Under a longer seven-day stress protocol with a two-day recovery, MOTS-c increased the proliferative capacity approximately six-fold (P = 8.95 × 10−22, n = 10).
  • Seahorse analysis showed that MOTS-c treatment significantly increased oxygen consumption rate in the presence of palmitate (P = 6.27 × 10−7, n = 11–12), while extracellular acidification rate remained unchanged.
  • FITC-labelled MOTS-c showed time-dependent nuclear translocation at 30 minutes, 4 hours, and 24 hours.
  • RNA-sequencing identified 69 differentially expressed genes (FDR < 5%), with heat-shock response and protein homeostasis as the most significantly enriched pathways; HSF1 was identified as a key regulatory factor, and siRNA knockdown of HSF1 reversed the protective effect of MOTS-c (P = 0.00027).[5]

These findings are from one published cell model. They should not be treated as a standard concentration for every cell line or experiment.

What Is Still Unknown

No dedicated cell-surface receptor for MOTS-c has been firmly established. The way externally added MOTS-c enters different cell types is also not fully clear.

Published metabolic data do not by themselves identify a single direct enzyme target.

Results can change with the cell line, peptide form, purity, buffer, culture medium, concentration, treatment time, and test method. A result from one model should not be assumed to occur in another model.

Cell and laboratory animal findings also cannot be used as proof of human or veterinary safety, effectiveness, or suitable dosing.

Laboratory Handling and COA Checks

The points below are basic quality-control checks for a research peptide.

ICH Q6A, Q3C, and Q1A were written for pharmaceutical quality systems, not specifically for an RUO MOTS-c product. They are cited here only as general references for separating identity, assay, impurities, residual solvents, and stability.

For more peptide-specific quality considerations, the EMA Guideline on the Development and Manufacture of Synthetic Peptides (effective June 2026) provides additional context, although it applies to medicinal-product development rather than routine RUO reagents.[6][7][8]

  • Identity: Intact-mass MS can show whether the main molecular mass is close to the expected value. It does not prove the full amino-acid sequence by itself. MS/MS or another suitable sequence method is needed when full sequence confirmation is required.
  • HPLC purity: HPLC shows the percentage of chromatographic peaks under the stated method. The COA should identify the method and acceptance limit. A high HPLC area percentage does not automatically equal the same percentage of peptide by vial weight.
  • Peptide content: If an experiment needs an accurate amount of peptide, check whether the COA reports actual peptide content separately from HPLC purity.
  • Oxidation impurities: MOTS-c contains two methionine residues and one tryptophan, all of which are susceptible to oxidation during synthesis, purification, and storage. Mono- and multi-oxidised species may co-elute or elute near the main peak on some HPLC methods. A stability-indicating HPLC or LC-MS method is recommended when oxidation is a concern.
  • High-molecular-weight species and aggregates: Dimerisation, oligomerisation, or aggregation may not be fully detected by routine HPLC area-normalisation methods and can affect biological readouts, especially in cell-based and animal-model studies. Separate assessment of aggregates may be warranted depending on the research application.
  • Water and counterions: Water, acetate, trifluoroacetate, salts, and other non-peptide material can affect the gross vial weight and concentration calculation. Counterion identity and content should be reported quantitatively when relevant—writing “acetate form” or “TFA salt” without the actual measured content is insufficient for accurate concentration calculations. The free peptide molecular weight (2,174.6 g/mol) does not include the mass contribution of counterions.
  • Residual solvents: Testing should match the solvents that may remain from synthesis, cleavage, purification, or drying. A generic statement that all solvents are absent is not enough without a defined method and reporting limit.
  • Endotoxins and microbiological controls: For sensitive cell assays or laboratory animal studies, the COA should also address bacterial endotoxins and appropriate microbiological controls. Endotoxin contamination can confound inflammatory, metabolic, and stress-response readouts.
  • Stability: Storage temperature, retest date, reconstituted-solution life, and freeze-thaw limits should come from batch or product stability data. They should not be guessed from a general peptide rule.

A COA is a batch quality record. It does not show that the material is safe for humans, suitable for veterinary use, or effective for any medical purpose.

HPLC, mass spectrometry, water testing, and residual-solvent testing each answer a different quality question.

Research References

  1. NCBI PubChem. MOTS-c (human), CID 155885767 (C101H152N28O22S2, 2,174.6 g/mol, exact mass 2,174.11 Da, XLogP3 −3.9, TPSA 890 Ų). https://pubchem.ncbi.nlm.nih.gov/compound/MOTS-c-_human
  2. NCBI Gene. MT-RNR1, Gene ID 4549 (mitochondrially encoded 12S rRNA). https://www.ncbi.nlm.nih.gov/gene/4549
  3. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3):443-454. doi:10.1016/j.cmet.2015.02.009. https://pmc.ncbi.nlm.nih.gov/articles/PMC4350682/
  4. Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metabolism. 2018;28(3):516-524.e7. doi:10.1016/j.cmet.2018.06.008. https://pmc.ncbi.nlm.nih.gov/articles/PMC6185997/
  5. Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021;12:470. doi:10.1038/s41467-020-20790-0. https://www.nature.com/articles/s41467-020-20790-0
  6. International Council for Harmonisation. ICH Q6A: Specifications—Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products. https://database.ich.org/sites/default/files/Q6A%20Guideline.pdf
  7. International Council for Harmonisation. ICH Q3C(R9): Impurities—Guideline for Residual Solvents. Step 4, January 2024. https://database.ich.org/sites/default/files/ICH_Q3C%28R9%29_Guideline_MinorRevision_2024_2024_Approved.pdf
  8. International Council for Harmonisation. ICH Q1A(R2): Stability Testing of New Drug Substances and Products. https://database.ich.org/sites/default/files/Q1A%28R2%29%20Guideline.pdf

Research Use Only Disclaimer

Research Use Only: The MOTS-c material described on this page is supplied for laboratory research use only and is not intended for human or veterinary use.

This article is provided for informational context regarding published laboratory research and general analytical and handling considerations. It does not constitute medical, clinical, veterinary guidance or treatment advice.

Related: Grey-market pairing of retatrutide with MOTS-c is mechanism folklore, not a co-administered evidence base—see our Retatrutide + MOTS-c stack evidence map (PubMed combo gap, CB4211 ≠ native MOTS-c, identity/COA checks; RUO only).